阿尔茨海默病连续谱中血浆与脑脊液GFAP水平的差异
这项多中心横断面研究比较了阿尔茨海默病连续谱中血浆与脑脊液GFAP水平,发现血浆GFAP在临床前AD即升高,且幅度变化大于脑脊液GFAP,鉴别Aβ阳性与阴性的准确性更高(AUC 0.69-0.86 vs 0.59-0.76),且仅在Aβ病理共存时与tau病理正相关。
要点
- 血浆GFAP在临床前AD阶段即显著升高,早于症状出现。
- 血浆GFAP鉴别Aβ阳性的AUC为0.69-0.86,优于脑脊液GFAP的0.59-0.76。
- 血浆GFAP与tau病理的正相关仅见于Aβ病理共存个体。
核心结论
- 血浆GFAP是检测和追踪反应性星形胶质增生及Aβ病理的敏感生物标志物,即使在AD早期阶段也是如此。
研究设计与样本
- 观察性横断面研究,纳入TRIAD队列300人、ALFA+队列384人、BioCogBank Paris Lariboisière队列187人,数据收集于2014年7月29日至2020年1月31日。
主要发现
- 临床前AD个体血浆GFAP显著高于认知正常Aβ阴性者(TRIAD:285.0 vs 185.1 pg/mL;ALFA+:169.9 vs 121.9 pg/mL)。
- 症状期AD连续谱中血浆GFAP更高(TRIAD:MCI Aβ阳性332.5 pg/mL,AD 388.1 pg/mL vs CU Aβ阴性185.1 pg/mL;Paris:MCI Aβ阳性368.6 pg/mL,AD痴呆376.4 pg/mL vs CU Aβ阴性161.2 pg/mL)。
- 血浆GFAP的变化幅度始终高于脑脊液GFAP。
- 血浆GFAP鉴别Aβ阳性与阴性的AUC为0.69-0.86,脑脊液GFAP为0.59-0.76。
- 血浆GFAP与tau病理正相关仅见于Aβ病理共存个体。
临床怎么用
- 血浆GFAP可作为无创生物标志物用于AD早期筛查和Aβ病理追踪。
- 在临床前AD阶段即可检测血浆GFAP升高,辅助识别Aβ阳性个体。
局限性
- 横断面设计无法推断因果关系或纵向变化。
- 结果主要来自三个特定队列,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). However, it is not known whether there are differences in blood GFAP levels across the entire AD continuum and whether its performance is similar to that of CSF GFAP. OBJECTIVE: To evaluate plasma GFAP levels throughout the entire AD continuum, from preclinical AD to AD dementia, compared with CSF GFAP. DESIGN, SETTING, AND PARTICIPANTS: This observational, cross-sectional study collected data from July 29, 2014, to January 31, 2020, from 3 centers. The Translational Biomarkers in Aging and Dementia (TRIAD) cohort (Montreal, Canada) included individuals in the entire AD continuum. Results were confirmed in the Alzheimer's and Families (ALFA+) study (Barcelona, Spain), which included individuals with preclinical AD, and the BioCogBank Paris Lariboisière cohort (Paris, France), which included individuals with symptomatic AD. MAIN OUTCOMES AND MEASURES: Plasma and CSF GFAP levels measured with a Simoa assay were the main outcome. Other measurements included levels of CSF amyloid-β 42/40 (Aβ42/40), phosphorylated tau181 (p-tau181), neurofilament light (NfL), Chitinase-3-like protein 1 (YKL40), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and levels of plasma p-tau181 and NfL. Results of amyloid positron emission tomography (PET) were available in TRIAD and ALFA+, and results of tau PET were available in TRIAD. RESULTS: A total of 300 TRIAD participants (177 women [59.0%]; mean [SD] age, 64.6 [17.6] years), 384 ALFA+ participants (234 women [60.9%]; mean [SD] age, 61.1 [4.7] years), and 187 BioCogBank Paris Lariboisière participants (116 women [62.0%]; mean [SD] age, 69.9 [9.2] years) were included. Plasma GFAP levels were significantly higher in individuals with preclinical AD in comparison with cognitively unimpaired (CU) Aβ-negative individuals (TRIAD: Aβ-negative mean [SD], 185.1 [93.5] pg/mL, Aβ-positive mean [SD], 285.0 [142.6] pg/mL; ALFA+: Aβ-negative mean [SD], 121.9 [42.4] pg/mL, Aβ-positive mean [SD], 169.9 [78.5] pg/mL). Plasma GFAP levels were also higher among individuals in symptomatic stages of the AD continuum (TRIAD: CU Aβ-positive mean [SD], 285.0 [142.6] pg/mL, mild cognitive impairment [MCI] Aβ-positive mean [SD], 332.5 [153.6] pg/mL; AD mean [SD], 388.1 [152.8] pg/mL vs CU Aβ-negative mean [SD], 185.1 [93.5] pg/mL; Paris: MCI Aβ-positive, mean [SD], 368.6 [158.5] pg/mL; AD dementia, mean [SD], 376.4 [179.6] pg/mL vs CU Aβ-negative mean [SD], 161.2 [67.1] pg/mL). Plasma GFAP magnitude changes were consistently higher than those of CSF GFAP. Plasma GFAP more accurately discriminated Aβ-positive from Aβ-negative individuals than CSF GFAP (area under the curve for plasma GFAP, 0.69-0.86; area under the curve for CSF GFAP, 0.59-0.76). Moreover, plasma GFAP levels were positively associated with tau pathology only among individuals with concomitant Aβ pathology. CONCLUSIONS AND RELEVANCE: This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD.
引用
- Benedet AL, Milà-Alomà M, Vrillon A, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurol. 2021. PMID: 34661615. doi:10.1001/jamaneurol.2021.3671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。